Cargando…
Safety of renal biopsy bleeding prophylaxis with desmopressin
BACKGROUND: Percutaneous renal biopsy (PRB) is invasive, and bleeding-related complications are a concern. Desmopressin (DDAVP) is a selective type 2 vasopressin receptor-agonist also used for haemostasis. AIM: To evaluate the side effects of intravenous (IV) weight-adjusted desmopressin preceding P...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489756/ https://www.ncbi.nlm.nih.gov/pubmed/34590925 http://dx.doi.org/10.1177/03000605211040764 |
_version_ | 1784578389922807808 |
---|---|
author | Barrios, R. Haridian Sosa Burguera Vion, Víctor Álvarez Nadal, Marta Cintra Cabrera, Melissa Elías Triviño, Sandra Villa Hurtado, Daniel Ortego, Sofía Fernández Lucas, Milagros Rivera-Gorrin, Maite |
author_facet | Barrios, R. Haridian Sosa Burguera Vion, Víctor Álvarez Nadal, Marta Cintra Cabrera, Melissa Elías Triviño, Sandra Villa Hurtado, Daniel Ortego, Sofía Fernández Lucas, Milagros Rivera-Gorrin, Maite |
author_sort | Barrios, R. Haridian Sosa |
collection | PubMed |
description | BACKGROUND: Percutaneous renal biopsy (PRB) is invasive, and bleeding-related complications are a concern. Desmopressin (DDAVP) is a selective type 2 vasopressin receptor-agonist also used for haemostasis. AIM: To evaluate the side effects of intravenous (IV) weight-adjusted desmopressin preceding PRB. METHODS: This was a retrospective study of renal biopsies performed by nephrologists from 2013 to 2017 in patients who received single-dose DDAVP pre-PRB. RESULTS: Of 482 PRBs, 65 (13.5%) received DDAVP (0.3 µg/kg); 55.4% of the PRBs were native kidneys. Desmopressin indications were altered platelet function analyser (PFA)-100 results (75.3% of the patients), urea >24.9 mmol/L (15.5%), antiplatelet drugs (6.1%) and thrombocytopaenia (3%). Of the 65 patients, 30.7% had minor asymptomatic complications, and 3 patients had major complications. Pre-PRB haemoglobin (Hb) <100 g/L was a risk factor for Hb decrease >10 g/L, and altered collagen-epinephrine (Col-Epi) time was a significant risk factor for overall complications. Mean sodium decrease was 0.6 ± 3 mmol/L. Hyponatraemia without neurological symptoms was diagnosed in two patients; no cardiovascular events occurred. CONCLUSION: Hyponatraemia after single-dose DDAVP is rare. A single IV dose of desmopressin adjusted to the patient’s weight is safe as pre-PRB bleeding prophylaxis. |
format | Online Article Text |
id | pubmed-8489756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84897562021-10-05 Safety of renal biopsy bleeding prophylaxis with desmopressin Barrios, R. Haridian Sosa Burguera Vion, Víctor Álvarez Nadal, Marta Cintra Cabrera, Melissa Elías Triviño, Sandra Villa Hurtado, Daniel Ortego, Sofía Fernández Lucas, Milagros Rivera-Gorrin, Maite J Int Med Res Retrospective Clinical Research Report BACKGROUND: Percutaneous renal biopsy (PRB) is invasive, and bleeding-related complications are a concern. Desmopressin (DDAVP) is a selective type 2 vasopressin receptor-agonist also used for haemostasis. AIM: To evaluate the side effects of intravenous (IV) weight-adjusted desmopressin preceding PRB. METHODS: This was a retrospective study of renal biopsies performed by nephrologists from 2013 to 2017 in patients who received single-dose DDAVP pre-PRB. RESULTS: Of 482 PRBs, 65 (13.5%) received DDAVP (0.3 µg/kg); 55.4% of the PRBs were native kidneys. Desmopressin indications were altered platelet function analyser (PFA)-100 results (75.3% of the patients), urea >24.9 mmol/L (15.5%), antiplatelet drugs (6.1%) and thrombocytopaenia (3%). Of the 65 patients, 30.7% had minor asymptomatic complications, and 3 patients had major complications. Pre-PRB haemoglobin (Hb) <100 g/L was a risk factor for Hb decrease >10 g/L, and altered collagen-epinephrine (Col-Epi) time was a significant risk factor for overall complications. Mean sodium decrease was 0.6 ± 3 mmol/L. Hyponatraemia without neurological symptoms was diagnosed in two patients; no cardiovascular events occurred. CONCLUSION: Hyponatraemia after single-dose DDAVP is rare. A single IV dose of desmopressin adjusted to the patient’s weight is safe as pre-PRB bleeding prophylaxis. SAGE Publications 2021-09-30 /pmc/articles/PMC8489756/ /pubmed/34590925 http://dx.doi.org/10.1177/03000605211040764 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Retrospective Clinical Research Report Barrios, R. Haridian Sosa Burguera Vion, Víctor Álvarez Nadal, Marta Cintra Cabrera, Melissa Elías Triviño, Sandra Villa Hurtado, Daniel Ortego, Sofía Fernández Lucas, Milagros Rivera-Gorrin, Maite Safety of renal biopsy bleeding prophylaxis with desmopressin |
title | Safety of renal biopsy bleeding prophylaxis with desmopressin |
title_full | Safety of renal biopsy bleeding prophylaxis with desmopressin |
title_fullStr | Safety of renal biopsy bleeding prophylaxis with desmopressin |
title_full_unstemmed | Safety of renal biopsy bleeding prophylaxis with desmopressin |
title_short | Safety of renal biopsy bleeding prophylaxis with desmopressin |
title_sort | safety of renal biopsy bleeding prophylaxis with desmopressin |
topic | Retrospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489756/ https://www.ncbi.nlm.nih.gov/pubmed/34590925 http://dx.doi.org/10.1177/03000605211040764 |
work_keys_str_mv | AT barriosrharidiansosa safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT burgueravionvictor safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT alvareznadalmarta safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT cintracabreramelissa safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT eliastrivinosandra safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT villahurtadodaniel safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT ortegosofia safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT fernandezlucasmilagros safetyofrenalbiopsybleedingprophylaxiswithdesmopressin AT riveragorrinmaite safetyofrenalbiopsybleedingprophylaxiswithdesmopressin |